Multiple Sclerosis Market expected to rise | Companies- Immune Response BioPharma

Multiple Sclerosis Market expected to rise | Companies- Immune Response BioPharma, Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, TG Therapeutics, Apimeds, Bayer HealthCare, Novartis, Biogen, Alkermes, Genentech, expected to drive market The Multiple Sclerosis market growth is driven by factors like increase in the prevalence of Multiple Sclerosis, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Multiple Sclerosis market report also offers comprehensive insights into the Multiple Sclerosis market size, share, Multiple Sclerosis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Multiple Sclerosis market size growth forward.

Some of the key highlights from the Multiple Sclerosis Market Insights Report: ●

●

●

Several key pharmaceutical companies, including Immune Response BioPharma, Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, TG Therapeutics, Apimeds, Bayer HealthCare, Novartis, Biogen, Alkermes, Genentech, and others, are developing novel products to improve the Multiple Sclerosis treatment outlook.

The total Multiple Sclerosis market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.

As per DelveInsight analysis, the Multiple Sclerosis market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Multiple Sclerosis Market Landscape Multiple Sclerosis Overview Multiple Sclerosis is an unpredictable, autoimmune disease that affects the central nervous system. In Multiple Sclerosis, body’s own immune system produces cells and proteins (antibodies) that attack the fatty substance, myelin, which is responsible for protecting the nerve fibers. This is often characterized by relapsing episodes of neurologic impairment followed by remissions.

The damaged myelin forms scar tissue (sclerosis). Often the nerve fiber is also damaged. When any part of the myelin sheath or nerve fiber is damaged or destroyed, nerve impulses traveling to and from the brain and spinal cord are distorted or interrupted.

People with Multiple Sclerosis generally develop symptoms in their late 20s, experiencing visual and sensory disturbances, limb weakness, gait problems and bladder and bowel syndromes. Initially, they may have partial recovery, but over time they develop progressive disability.

Multiple Sclerosis affected individuals may experience a variety of symptoms, physically, emotionally, mentally and psychologically. The severity and types of symptoms differ among the individuals; thus symptoms differ among different people.

There are four major categories in Multiple Sclerosis. These are: Relapsing-Remitting Multiple Sclerosis, Secondary-Progressive Multiple Sclerosis, Primary-Progressive Multiple Sclerosis, and Progressive-Relapsing Multiple Sclerosis.

There is no single test used to diagnose Multiple Sclerosis. The disease is confirmed when symptoms and signs develop and are related to different parts of the nervous system at more than one interval in time and after other alternative diagnoses have been excluded.

Doctors use different tests to rule out or confirm the diagnosis. In addition to complete medical history, physical examination, and a detailed neurological examination, a doctor may recommend: MRI scans of the brain and spinal cord to look for the characteristic lesions of MS. A special dye or contrast agent may be injected into a vein to enhance brain images of the active MS lesions.

Lumbar puncture (sometimes called a spinal tap) to obtain a sample of cerebrospinal fluid and examine it for proteins and inflammatory cells associated with the disease.

Spinal tap analysis also can rule out diseases that may look like MS. Do you know the treatment paradigms for different countries? Download our Multiple Sclerosis Market Sample Report Multiple Sclerosis Treatment Market The Multiple Sclerosis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Multiple Sclerosis market trends by analyzing the impact of current Multiple Sclerosis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Multiple Sclerosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key

opinion leaders. The calculated Multiple Sclerosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Multiple Sclerosis market in 7MM is expected to witness a major change in the study period 2019-2032.

Multiple sclerosis Emerging Drugs Ublituximab: TG Therapeutics Ublituximab (TG-1101) is an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. When ublituximab binds to the B-cell it triggers a series of immunological reactions (including antibody-dependent cellular cytotoxicity [ADCC] and complement dependent cytotoxicity [CDC]), leading to destruction of the cell. Additionally, ublituximab is uniquely designed, to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, has been shown to enhance the potency of ublituximab, especially the ADCC activity. In September 2021, TG Therapeutics announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody, as a treatment for patients with relapsing forms of multiple sclerosis (RMS). The submission was based on the results of the ULTIMATE I & II trials, two identical Phase 3, randomized, global, multi-center, double-blinded, active-controlled trials evaluating ublituximab compared to teriflunomide in patients with RMS. The ULTIMATE I & II trials were conducted under a Special Protocol Assessment (SPA) agreement with the FDA. IMU-838: Immunic Vidofludimus calcium (IMU-838) is a small molecule investigational drug under development as an oral tablet formulation for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. On July 1, 2021, Immunic announced U.S. Food and Drug Administration, or FDA, clearance of its Investigational New Drug, or IND, application for the phase 3 ENSURE program of vidofludimus calcium in patients with

RMS.

The

ENSURE

program

comprises

two multicenter, randomized,

double-blind phase 3 trials designed to evaluate the efficacy, safety, and tolerability of vidofludimus calcium versus placebo in RMS patients. Each of the trials, titled ENSURE-1 and ENSURE-2, is expected to enroll approximately 1,050 adult patients with active RMS at more than 100 sites in 14 countries, including the United States,

Latin America, Central and Eastern Europe, and India. Patients will be randomized in a double-blinded fashion to either 30 mg daily doses of vidofludimus calcium or placebo and the primary endpoint for both trials is time to first relapse up to 72 weeks.

Key secondary endpoints include volume of new T2-lesions, time to confirmed disability progression, time to sustained clinically relevant changes in cognition, and percentage of whole brain volume change, grey matter volume, and white matter volume. The ENSURE trials will be run concurrently. The first patient has been enrolled in November 2021.

ATA188: Atara Biotherapeutics ATA188, is an off-the-shelf, allogeneic EBV T-cell that utilizes a targeted antigen recognition technology that enables the T‑Cells we administer to selectively identify cells expressing the EBV antigens that may be important in the pathophysiology of MS. ANK-700: ANOKION ANK-700 is an investigational treatment for RRMS. It encompasses a previously identified myelin antigen that is implicated in driving Multiple Sclerosis. The antigen is delivered to the liver and immune system with the liver targeting glycosylation signature. The drug is currently in Phase I stage of clinical trila evaluation to treat multiple sclerosis.

Multiple Sclerosis Key Companies ● ● ● ● ● ● ● ● ● ● ●

Immune Response BioPharma Clene Nanomedicine Sanofi Merck Healthcare KGaA TG Therapeutics Apimeds Bayer HealthCare Novartis Biogen Alkermes Genentech

For more information, visit Multiple Sclerosis Market Analysis, Patient Pool, and Emerging Therapies Scope of the Multiple Sclerosis Market Report:

● ● ● ● ● ● ●

10 Years Forecast 7MM Coverage Descriptive overview of Multiple Sclerosis, causes, signs and symptoms, diagnosis, treatment Comprehensive insight into Multiple Sclerosis epidemiology in the 7MM Multiple Sclerosis marketed and emerging therapies Multiple Sclerosis companies Multiple Sclerosis market drivers and barriers

Key Questions Answered in the Multiple Sclerosis Market Report 2032:

● ● ● ●

What was the Multiple Sclerosis market share distribution in 2019, and how would it appear in 2032?

What is the total Multiple Sclerosis market size and the market size by therapy across the 7MM for the study period (2019-32)?

What are the important findings from 7MM, and which country will have the greatest Multiple Sclerosis market size from 2019-32?

During the study period (2019-2032), at what CAGR is the Multiple Sclerosis market projected to expand at 7MM?

Table of Contents: 1 Multiple Sclerosis Market Key Comprehensive Insights 2 Multiple Sclerosis Market Report Introduction 3 Competitive Intelligence Analysis for Multiple Sclerosis 4 Multiple Sclerosis Market Analysis Overview at a Glance 5 Executive Summary of Multiple Sclerosis 6 Multiple Sclerosis Epidemiology and Market Methodology 7 Multiple Sclerosis Epidemiology and Patient Population 8 Multiple Sclerosis Patient Journey 9 Multiple Sclerosis Treatment Algorithm, Multiple Sclerosis Current Treatment, and Medical Practices 10 Key Endpoints in Multiple Sclerosis Clinical Trials 11 Multiple Sclerosis Marketed Therapies 12 Multiple Sclerosis Emerging Therapies 13 Multiple Sclerosis: 7 Major Market Analysis 14 Attribute analysis 15 Access and Reimbursement Overview of Multiple Sclerosis 16 Multiple Sclerosis Market Key Opinion Leaders Reviews 18 Multiple Sclerosis Market Drivers 19 Multiple Sclerosis Market Barriers

20 21 22 23

SWOT Analysis Disclaimer DelveInsight Capabilities About DelveInsight

Related Reports: Multiple Sclerosis Epidemiology 2032 DelveInsight's "Multiple Sclerosis - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Multiple Sclerosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

About DelveInsight: DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Contact Us: Kritika Rehani krehani@delveinsight.com +91-9650213330 www.delveinsight.com